Among those genes, BIRC5 and EIF4EBP1 exhibited higher expression and were associated with poor clinical outcomes in KIRC, KIRP, and LIHC; IFNG had elevated expression and different clinical outcomes in BLCA and KIRP; ATG16L2 and BNIP3 showed various expression and were associated with clinical outcomes in multiple cancer types (Figure 2A). This evidence concerns the gene BIRC5 and bladder transitional cell carcinoma.